At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 114 enrolled
Drug / intervention
Sulindacdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NSAID Effects on Clinical and Imaging Breast Biomarkers
In Brief
A Phase 2 clinical trial evaluating Sulindac for Inflammation and 3 related conditions. Completed, enrolled 114 participants across 2 sites.
Detailed Summary
This study has two purposes. One is to determine if daily sulindac decreases breast density; a risk factor for breast cancer development. The second is to determine whether sulindac reduces pain and stiffness associated with regular use of aromatase inhibitors given for the treatment of breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Cancer, Pain, Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedJan 2013
Primary CompletionFeb 2019
Study CompletionMar 2019
TodayJul 2026
First PostedJan 7, 2013
Enrollment StartDec 1, 2012
Primary CompletionFeb 7, 2019
Study CompletionMar 11, 2019
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 13.5 years ago
Interventions
Sulindacdrug